Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @LaboratoryLiz
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @LaboratoryLiz
-
.
@GileadSciences CEO O’Day says patients will be focus of its#2019nCoV response, not patentshttps://twitter.com/jeff_cranmer/status/1225241449895120896 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
And here's our table tallying ongoing trials of therapeutics to treat
#2019nCoV#coronavirus https://www.biocentury.com/article/304368 pic.twitter.com/l2rYdPE6bS
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
3. Gilead says it's "investing pretty heavily" and working “night and day” to ramp up manufacturing for
#remdesivir 4.@WHO says#remdesivir is the most promising candidate to treat#2019nCoVhttps://www.biocentury.com/article/304374Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A newsy couple of days for
@GileadSciences and its antiviral to treat#coronavirus: 1.#remdesivir almost completely resolves symptoms of U.S. patient 2.$GILD plans to enroll patients in 2 Chinese trials mid-Febhttps://www.biocentury.com/article/304364Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Elizabeth S. Eaton proslijedio/la je Tweet
Gilead preparing a trial in China of remdesivir to treat 2019-nCoV: https://www.biocentury.com/article/304364 . Meanwhile, at least 9 trials of #2019-nCoV therapies are underway. https://www.biocentury.com/article/304364 All BioCentury coverage of the outbreak is in front of the paywall at https://www.biocentury.com/coronavirus .pic.twitter.com/MR9Bhpq0Pn
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Before
#JPM20 kicked off this week, I spoke with@AligosThera CEO Blatt about the company's $125M series B and its three different approaches to treat#HBVhttps://twitter.com/LifeSciComms/status/1218226359337725954 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ehsan Bahrami told
@BioCentury he was blocked from traveling to the U.S. for#ASH19 because he is Iranian. His team won an Achievement Award for an abstract on the use of a#CRISPR screen in cells from#leukemia patientshttps://twitter.com/BioCentury/status/1204558959392305155 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Elizabeth S. Eaton proslijedio/la je Tweet
Trump to nominate Hahn as FDA commissionerhttps://www.biocentury.com/bc-extra/politics-policy/2019-10-01/trump-nominate-hahn-fda-commissioner …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Elizabeth S. Eaton proslijedio/la je Tweet
AveXis knew about Zolgensma data manipulation and didn't tell FDA. SMA gene therapy will stay on the market, but a blow to
$NVS as FDA weighs possible criminal/civil penaltieshttps://www.biocentury.com/bc-extra/company-news/2019-08-06/fda-avexis-manipulated-potency-data-zolgensma …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@BioCentury's@Laurenmmartz spoke with$fixx, which said there were important differences in USC's AAV manufacturing, which are "key to efficiency"https://twitter.com/jeff_cranmer/status/1154620951973126144 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Elizabeth S. Eaton proslijedio/la je Tweet
Great story on
@Clover_Health from@LaboratoryLiz in@BioCentury yesterday. Details:https://twitter.com/BioCentury/status/1149106116590264320 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Elizabeth S. Eaton proslijedio/la je Tweet
Great Emerging Company Profile from
@BioCentury on Sherlock Biosciences and its mission to leverage#CRISPR and#syntheticbiology to rapidly and accurately detect disease. Read here http://ow.ly/mvxZ50uI3Jz pic.twitter.com/71dKXBdrIX
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Elizabeth S. Eaton proslijedio/la je Tweet
#Phishing Warning! Someone is mimicking BioCentury's Twitter page on the domain http://gangjinwang88.com , to trick people into disclosing their Twitter credentials. The creators of that page are likely sending fake Twitter emails directing them to the site. Please take care.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Some highlights from today's
#orkambi debate:@KerryMP speaks in favor of#CrownUseLicense: "The government needs to step in and help."@SeemaKennedy says she has "a moral obligation" to consider options other than deal w/@VertexPharmaPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Paul Hudson to take the helm at
@sanofihttps://twitter.com/BioCentury/status/1136951096872787969 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The latest on
#Orkambi in the U.K: Parents of children with#cysticfibrosis have formed a buyer's club to purchase generic versions of#Orkambi and#Kalydeco from an outside manufacturer, with eyes on a Crown Use Licensehttps://bit.ly/2Z3UFe3Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
I spoke with
#Vigeo CEO Jing Watnick about how its lead candidate reprograms macrophages, induces apoptosis and increases T cell infiltration to treat cancer. The co has raised $27.5M from#Morningside, and is now on the hunt for a ~$50M series Chttps://twitter.com/BioCentury/status/1134542636642185218 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Elizabeth S. Eaton proslijedio/la je Tweet
On the eve of
#ASCO19, Thrive launches with $110M series A to take on big hitters@GrailBio,@GuardantHealth and develop a liquid biopsy test for the primary care setting.@StephenPHansen reports in the latest#BCEmergingCompanyProfilehttps://buff.ly/2XmGBfnHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
In its response to the offer,
$VRTX says it's the "same annual spend" and took issue with how NHS characterized the negotiations, hinting that the end may *not* be in sight for the#Orkambi impasse#cysticfibrosisPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.